# Forensic Dossier: Study Forensics: Novel cholesterol drug dramatically lowers LDL but cardiovascular outcomes unknown

**Run ID:** `praxis_study-forensics-032_Claude_Sonnet_c802dc`  
**Task:** study-forensics-032 | study_forensics | medium | study_forensics  
**Timestamp:** 2026-04-07T07:57:49.259767+00:00  
**Task Family:** overclaim  
**Trap Type:** surrogate_endpoint_overclaim  
**Ambiguity:** low  

## Executive Summary

**Agents tested:** Claude Sonnet
**Winner:** Claude Sonnet — **71.4/100** (margin: 0.0)
**Failure modes:** decorative_self_check, decorative_uncertainty, missed_key_insight
**Forensic flags:** 1
**Consistency findings:** 8
**Answer convergence:** all agents agree

## Score Matrix

| Agent | Correctness | Support Strength | Structural Reaso | Assumption Disci | Uncertainty Hand | Alternative Hypo | Self Monitoring  | Insight Depth | Mechanism Qualit | Communication Ef | **Total** |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Claude Sonnet | 30.0/30 | 2.4/8 | 5.4/8 | 4.8/6 | 3.3/6 | 4.5/6 | 0.0/8 | 8.0/8 | 3.0/10 | 10.0/10 | **71.4/100** |

## Study Forensics Audit

### Claude Sonnet

**Classification:** `overclaim` [+] (gold: `overclaim`)
**Finding Recall:** 50%
**Matched Findings:** conclusion_exceeds_results
**Missed Findings:** unsupported_generalization
**Extra Findings:** correlation_as_causation

## Reasoning Integrity Audit

### Claude Sonnet
**Classification:** Correct and well-supported
**Load-bearing steps:** 1 / 5

## Mechanism Analysis

### Claude Sonnet
| Aspect | Status |
|--------|--------|
| Concept named | :x: none |
| Mechanism described | :white_check_mark: (1 sentence(s)) |
| Grounded to case | :x: (0 sentence(s)) |

**Missing:** concept not named, mechanism not grounded to case data

## Grounding Audit

### Claude Sonnet
Conclusion claims: 1
- Direct support: 0
- Indirect support: 1
- Unsupported: 0
- Contradicted: 0


## Forensic Flags

### Claude Sonnet

- **[STYLISTIC]** `unnamed_mechanism`: Describes mechanism without naming the concept — under-explicit
  - `steps[4]`: "Determined this represents overclaim because cardiovascular protection claims exceed the evidence fr"


## Evidence Map

### Claude Sonnet

**Correctness:** 30.0/30
  - (+) `final_answer`: "overclaim"
    _Agent's answer for correctness check_
  - Note: Exact match

**Support Strength:** 2.4/8
  - (+) `final_answer`: "overclaim"
    _Conclusion grounded by reasoning chain_
  - Note: Support classification: 0 load-bearing, 1 supporting, 0 mentioned / 5
  - Note: Reasoning graph confirms conclusion grounding

**Structural Reasoning:** 5.4/8
  - (+) `steps[2]`: "Recognized that company executives made claims about 'major breakthrough in cardiovascular protection' and transforming "
    _Most informative reasoning step_
  - Note: 5 reasoning steps
  - Note: Low step utility: 1/5 steps contribute

**Assumption Discipline:** 4.8/6
  - (+) `assumptions[2]`: "The claims about cardiovascular protection are based solely on LDL reduction data"
    _Most substantive assumption_
  - Note: 4/4 substantive assumptions

**Uncertainty Handling:** 3.3/6
  - (+) `uncertainties[2]`: "Whether there are established regulatory precedents for approval based on LDL reduction alone in this population"
    _Most substantive uncertainty_
  - (+) `confidence`: "confidence: 0.92"
    _Stated confidence level_
  - (-) `uncertainties[1]`: "The exact wording used by executives (though the text suggests strong causal claims)"
    _Listed but never addressed in reasoning_
  - (-) `uncertainties[2]`: "Whether there are established regulatory precedents for approval based on LDL reduction alone in this population"
    _Listed but never addressed in reasoning_
  - Note: 3 uncertainties (3 substantive)
  - Note: 2 decorative uncertainty(ies)

**Alternative Hypothesis Quality:** 4.5/6
  - (+) `alternative_hypotheses[0]`: "mechanism_vs_evidence - could argue they're applying LDL mechanism to cardiovascular outcomes"
    _Most substantive alternative hypothesis_
  - Note: 2 alternative hypotheses considered
  - Note: 2/2 genuinely diverse alternatives

**Self Monitoring Quality:** 0.0/8
  - (+) `self_check[2]`: "Checked that I'm not fabricating problems - the overclaim is clearly present"
    _Most substantive self-verification step_
  - (-) `self_check[0]`: "Verified the text explicitly states no cardiovascular events were tracked"
    _Fluff self-check_
  - Note: 4 self-check items
  - Note: Self-check quality: 0 deep, 0 arithmetic, 4 fluff

**Mechanism Quality:** 3.0/10
  - (+) `(mechanism analysis)`: "Determined this represents overclaim because cardiovascular protection claims exceed the evidence from a lipid-only tria"
    _Mechanism description_
  - Note: Describes mechanism but does not name concept

**Communication Efficiency:** 10.0/10
  - Note: Signal density: 0.74, 270 words

**Insight Depth:** 8.0/8
  - Note: Key insights: 2 full / 2


## Failure Analysis

### Claude Sonnet

**MODERATE:**
- **Missed Key Insight** `[MEDIUM CONFIDENCE]`: Missed expected finding: unsupported_generalization
  - `(task expectation)`: "Expected: unsupported_generalization"
  - _Impacts: insight_depth_

**MINOR:**
- **Decorative Self Check** `[HEURISTIC]`: All 4 self-checks appear to be fluff — no substantive verification
  - `self_check[0]`: "Verified the text explicitly states no cardiovascular events were tracked"
  - _Impacts: self_monitoring_quality_

**STYLISTIC:**
- **Decorative Uncertainty** `[HEURISTIC]`: Uncertainty 'The exact wording used by executives (though the text sugges...' is listed but not addressed
  - `uncertainties[1]`: "The exact wording used by executives (though the text suggests strong causal claims)"
  - _Impacts: uncertainty_handling_
- **Decorative Uncertainty** `[HEURISTIC]`: Uncertainty 'Whether there are established regulatory precedents for appr...' is listed but not addressed
  - `uncertainties[2]`: "Whether there are established regulatory precedents for approval based on LDL reduction alone in thi"
  - _Impacts: uncertainty_handling_


## Consistency & Grounding Audit

### Claude Sonnet

- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 1 has low overlap with final answer (0/9 content words)
  - `key_claims[0]`: "Company claims 'major breakthrough in cardiovascular protection' based on LDL reduction data only"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 2 has low overlap with final answer (0/15 content words)
  - `key_claims[1]`: "Claims drug will 'transform outcomes for patients at high risk of heart attack and stroke' without c"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 3 has low overlap with final answer (0/9 content words)
  - `key_claims[2]`: "Plans for accelerated approval based solely on LDL reduction from 12-week trial"
- **[WARN]** `[HEURISTIC]` `decorative_uncertainty`: Uncertainty 2 appears decorative — not addressed in reasoning or self-check
  - `uncertainties[1]`: "The exact wording used by executives (though the text suggests strong causal claims)"
- **[WARN]** `[HEURISTIC]` `decorative_uncertainty`: Uncertainty 3 appears decorative — not addressed in reasoning or self-check
  - `uncertainties[2]`: "Whether there are established regulatory precedents for approval based on LDL reduction alone in thi"
- **[NOTE]** `[HEURISTIC]` `weak_alternative`: Alternative hypothesis 1 is stated without rejection reasoning
  - `alternative_hypotheses[0]`: "mechanism_vs_evidence - could argue they're applying LDL mechanism to cardiovascular outcomes"
- **[NOTE]** `[HEURISTIC]` `weak_alternative`: Alternative hypothesis 2 is stated without rejection reasoning
  - `alternative_hypotheses[1]`: "solid - if the claims were limited to LDL reduction only"
- **[NOTE]** `[MEDIUM CONFIDENCE]` `mechanism_gap`: Causal mechanism described but underlying concept not named
  - `final_answer`: "overclaim"


## Agent Profiles

### Claude Sonnet (claude-sonnet-4-20250514)
**Parse OK:** True | **Latency:** 10424ms

**Final Answer:** overclaim

**Confidence:** 0.92

**Assumptions:**
- The Phase 2 trial only measured LDL cholesterol reduction and liver safety
- No cardiovascular outcomes were measured in this 12-week trial
- The claims about cardiovascular protection are based solely on LDL reduction data
- This is a pharmaceutical company announcement, not a peer-reviewed publication

**Reasoning Steps:**
1. Identified that the study measured only LDL cholesterol reduction (65%) and liver safety over 12 weeks
2. Noted that no cardiovascular events were tracked in this trial
3. Recognized that company executives made claims about 'major breakthrough in cardiovascular protection' and transforming outcomes for heart attack and stroke
4. Identified the disconnect between measured outcomes (LDL levels) and claimed benefits (cardiovascular protection)
5. Determined this represents overclaim because cardiovascular protection claims exceed the evidence from a lipid-only trial

**Key Claims:**
- Company claims 'major breakthrough in cardiovascular protection' based on LDL reduction data only
- Claims drug will 'transform outcomes for patients at high risk of heart attack and stroke' without cardiovascular outcome data
- Plans for accelerated approval based solely on LDL reduction from 12-week trial

**Alternative Hypotheses:**
- mechanism_vs_evidence - could argue they're applying LDL mechanism to cardiovascular outcomes
- solid - if the claims were limited to LDL reduction only

**Uncertainties:**
- Whether LDL reduction of this magnitude in this population has established cardiovascular benefit
- The exact wording used by executives (though the text suggests strong causal claims)
- Whether there are established regulatory precedents for approval based on LDL reduction alone in this population

**Self-Verification:**
- Verified the text explicitly states no cardiovascular events were tracked
- Confirmed the cardiovascular protection claims are present in the text
- Checked that I'm not fabricating problems - the overclaim is clearly present
- Ensured I'm focusing on what was actually measured vs. what was claimed

**Dimension Scores:**
- Correctness: 30.0/30 `##########`
- Support Strength: 2.4/8 `###.......`
- Structural Reasoning: 5.4/8 `######....`
- Assumption Discipline: 4.8/6 `########..`
- Uncertainty Handling: 3.3/6 `#####.....`
- Alternative Hypothesis Quality: 4.5/6 `#######...`
- Self Monitoring Quality: 0.0/8 `..........`
- Insight Depth: 8.0/8 `##########`
- Mechanism Quality: 3.0/10 `###.......`
- Communication Efficiency: 10.0/10 `##########`


## Final Verdict

**Solo run: Claude Sonnet** scored **71.4/100**.

**Best per dimension:**
- Correctness: Claude Sonnet (30.0/30)
- Support Strength: Claude Sonnet (2.4/8)
- Structural Reasoning: Claude Sonnet (5.4/8)
- Assumption Discipline: Claude Sonnet (4.8/6)
- Uncertainty Handling: Claude Sonnet (3.3/6)
- Alternative Hypothesis Quality: Claude Sonnet (4.5/6)
- Self Monitoring Quality: Claude Sonnet (0.0/8)
- Insight Depth: Claude Sonnet (8.0/8)
- Mechanism Quality: Claude Sonnet (3.0/10)
- Communication Efficiency: Claude Sonnet (10.0/10)

**Latency vs Quality:**

| Agent | Latency | Score | Points/sec |
|-------|---------|-------|------------|
| Claude Sonnet | 10.4s | 71.4/100 | 6.8 |

Failure modes observed: decorative_self_check, decorative_uncertainty, missed_key_insight.
